GPCM
MRNS

Granite Point Capital Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Granite Point Capital Management’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-472,056
Closed -$3.14M – 121
2022
Q3 		$3.14M Hold
472,056
– – 1.27% 11
2022
Q2 		$2.29M Hold
472,056
– – 0.58% 19
2022
Q1 		$4.41M Buy
472,056
+52,732
+13% +$524K 0.92% 23
2021
Q4 		$4.98M Hold
419,324
– – 0.84% 20
2021
Q3 		$4.77M Hold
419,324
– – 0.37% 27
2021
Q2 		$7.52M Sell
419,324
-50,000
-11% -$804K 0.28% 21
2021
Q1 		$7.26M Sell
469,324
-50
-0% -$723 0.27% 30
2020
Q4 		$5.73M Hold
469,374
– – 0.29% 30
2020
Q3 		$6.03M Sell
469,374
-93,906
-17% -$810K 0.33% 37
2020
Q2 		$5.72M Buy
563,280
+91,005
+19% +$837K 0.29% 38
2020
Q1 		$3.83M Sell
472,275
-202,725
-30% -$1.76M 2.17% 14
2019
Q4 		$5.83M Sell
675,000
-210,205
-24% -$1.18M 0.91% 16
2019
Q3 		$5.45M Buy
885,205
+50,000
+6% +$404K 0.85% 9
2019
Q2 		$13.9M Buy
835,205
+73,853
+10% +$1.28M 0.93% 16
2019
Q1 		$12.7M Buy
761,352
+96,510
+15% +$1.39M 1.23% 14
2018
Q4 		$7.63M Buy
664,842
+400,000
+151% +$8.09M 1.54% 11
2018
Q3 		$10.6M Sell
264,842
-394,738
-60% -$11.2M 0.7% 23
2018
Q2 		$18.7M Hold
659,580
– – 1.67% 12
2018
Q1 		$10.1M Buy
659,580
+89,868
+16% +$2.14M 0.97% 8
2017
Q4 		$18.6M Sell
569,712
-101,500
-15% -$2.74M 1.82% 4
2017
Q3 		$15.8M Buy
671,212
+479,600
+250% +$5.38M 3.32% 4
2017
Q2 		$1.05M Sell
191,612
-2,138
-1% -$11.6K 0.26% 60
2017
Q1 		$1.37M Buy
+193,750
New +$1.04M 0.41% 36

Other funds holding MRNS

LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
AC
Antara Capital New York $30.2K AUM 5.24% 1-Year Est. Return

Granite Point Capital Management's MRNS Position: Q4 2022 in Review

Granite Point Capital Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q4 2022, closing a stake of 472,056 shares — an estimated $3.14M sold.

Granite Point Capital Management first reported a position in MRNS in Q1 2017 and held it in 23 quarters. The position peaked at $18.7M in Q2 2018. 74 funds tracked by Wall St. Rank hold MRNS as of Q4 2022.

  • Granite Point Capital Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q4 2022 after selling out during the quarter.
  • Granite Point Capital Management sold 472,056 Marinus Pharmaceuticals, Inc shares in Q4 2022, an estimated $3.14M.
  • Granite Point Capital Management first reported a position in Marinus Pharmaceuticals, Inc in Q1 2017 and held it in 23 quarters.
  • Granite Point Capital Management's Marinus Pharmaceuticals, Inc position peaked at $18.7M in Q2 2018.
  • 74 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2022.

Based on Granite Point Capital Management's 13F filing for Q4 2022, filed 7 Feb 2023.